Literature DB >> 17330281

Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors.

Terry A McNearney1, John D Reveille, Michael Fischbach, Alan W Friedman, Jeffrey R Lisse, Niti Goel, Filemon K Tan, Xiaodong Zhou, Chul Ahn, Carol A Feghali-Bostwick, Marvin Fritzler, Frank C Arnett, Maureen D Mayes.   

Abstract

OBJECTIVE: To determine the relative contributions of genetic, clinical, serologic, sociodemographic, and behavioral/psychological variables to early pulmonary involvement in the Genetics versus Environment in Scleroderma Outcome Study cohort.
METHODS: At the baseline visit (V0), 203 patients with systemic sclerosis (SSc) were examined (104 whites, 39 African Americans, and 60 Hispanics). We obtained sociodemographic, behavioral/psychological (illness behavior, social support, learned helplessness, smoking, drinking), clinical, serologic (autoantibodies), and genetic (HLA class II and FBN1 genotypes) factors; pulmonary function test results; electrocardiograms; and chest radiographs. Data analysis included Fisher's exact test, chi-square test, Student's t-test, analysis of variance, and stepwise linear and logistic regression methods.
RESULTS: Significant pulmonary involvement was seen in 25% of patients within 2.8 years of SSc diagnosis. At V0, pulmonary fibrosis was significantly higher in African Americans compared with whites or Hispanics. African Americans had significantly lower percent predicted forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV(1)) compared with whites and significantly lower percent predicted diffusing capacity for carbon monoxide (DLCO) compared with whites and Hispanics. Significant, independent associations impacting early pulmonary involvement included African American ethnicity, skin score, serum creatinine and creatine phosphokinase values, hypothyroidism, and cardiac involvement. Anticentromere antibody seropositivity was a significant, independent, protective factor for restrictive lung disease and FVC or DLCO values. African Americans had significantly increased frequencies of anti-topoisomerase I, fibrillarin, and RNP autoantibodies compared with whites. African Americans scored significantly lower on the Interpersonal Support Evaluation List and significantly higher on the Illness Behavior Questionnaire.
CONCLUSION: Early pulmonary involvement in SSc appears to be influenced by several factors delineated by ethnicity, including racial, socioeconomic, behavioral, and serologic determinants.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17330281     DOI: 10.1002/art.22532

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  54 in total

Review 1.  Pulmonary arterial hypertension associated with systemic sclerosis.

Authors:  Stephen C Mathai; Paul M Hassoun
Journal:  Expert Rev Respir Med       Date:  2011-04       Impact factor: 3.772

2.  Pulmonary manifestations of systemic autoimmune diseases.

Authors:  Manole Cojocaru; Inimioara Mihaela Cojocaru; Isabela Silosi; Camelia Doina Vrabie
Journal:  Maedica (Bucur)       Date:  2011-07

Review 3.  Investigational approaches to therapies for idiopathic pulmonary fibrosis.

Authors:  Richard H Gomer; Mark L Lupher
Journal:  Expert Opin Investig Drugs       Date:  2010-06       Impact factor: 6.206

Review 4.  Lung involvement in systemic sclerosis.

Authors:  Paul M Hassoun
Journal:  Presse Med       Date:  2010-12-30       Impact factor: 1.228

5.  Determinants of work disability in patients with systemic sclerosis: a longitudinal study of the GENISOS cohort.

Authors:  Roozbeh Sharif; Maureen D Mayes; Perry M Nicassio; Emilio B Gonzalez; Hilda Draeger; Terry A McNearney; Rosa M Estrada-Y-Martin; Deepthi K Nair; John D Reveille; Frank C Arnett; Shervin Assassi
Journal:  Semin Arthritis Rheum       Date:  2011-03-22       Impact factor: 5.532

Review 6.  Interstitial lung disease in scleroderma.

Authors:  Sara R Schoenfeld; Flavia V Castelino
Journal:  Rheum Dis Clin North Am       Date:  2015-02-26       Impact factor: 2.670

Review 7.  Systemic sclerosis: a world wide global analysis.

Authors:  Paola Coral-Alvarado; Aryce L Pardo; Natalia Castaño-Rodriguez; Adriana Rojas-Villarraga; Juan-Manuel Anaya
Journal:  Clin Rheumatol       Date:  2009-03-11       Impact factor: 2.980

8.  African-American race and mortality in interstitial lung disease: a multicentre propensity-matched analysis.

Authors:  Ayodeji Adegunsoye; Justin M Oldham; Shashi K Bellam; Jonathan H Chung; Paul A Chung; Kathleen M Biblowitz; Steven Montner; Cathryn Lee; Scully Hsu; Aliya N Husain; Rekha Vij; Gokhan Mutlu; Imre Noth; Matthew M Churpek; Mary E Strek
Journal:  Eur Respir J       Date:  2018-06-14       Impact factor: 16.671

Review 9.  Scleroderma lung disease.

Authors:  Joshua J Solomon; Amy L Olson; Aryeh Fischer; Todd Bull; Kevin K Brown; Ganesh Raghu
Journal:  Eur Respir Rev       Date:  2013-03-01

10.  Influence of interstitial lung disease on outcome in systemic sclerosis: a population-based historical cohort study.

Authors:  Philippe R Bauer; Dante N Schiavo; Thomas G Osborn; David L Levin; Jennifer St Sauver; Andrew C Hanson; Darrell R Schroeder; Jay H Ryu
Journal:  Chest       Date:  2013-08       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.